As Valentine's Day approaches, the UConn School of Pharmacy wants to celebrate the chemistry we find in and out of our ...

Eli Lilly has made a foray into the radiopharmaceuticals ... radiopharmaceutical manufacturing facility on Lilly’s campus in Indianapolis, clearing one of the key obstacles to entering the ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Lilly's fourth-quarter earnings, released before the market opened Thursday, surpassed analysts' expectations by millions.

Lilly expects full-year earnings in the range of $22.50 to $24 per share, with revenue in the range of $58 billion to $61 billion. This story was generated by Automated Insights ( ...

Eli Lilly has named Winselow Tucker as President and General Manager for India. Tucker will oversee operations, including the Lilly India commercial organization and the Lilly Capability Centre India.

With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading global ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.